The reiteration of a Neutral rating and maintenance of the $128 price target by Cantor Fitzgerald suggests a stable outlook for Sarepta Therapeutics without immediate significant positive or negative catalysts. This analysis is based on the information provided by the analyst and does not introduce new data that would significantly alter the stock's trajectory in the short term.